Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now full pipeline small index

Meningococcal Infections: full-pipeline trial registry

1 of 5 indexed Meningococcal Infections trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Meningococcal Infections: 5 US clinical trials tracked, 1 recruiting.

Meningococcal Infections is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi Pasteur, a Sanofi Company, running 3 of these trials.

Enrollment posture brief

Registry condition meningococcal-infections

OPEN 1 | RECR 20% | LATE 2 | EARLY 3 | RANK #3391 | SPON 3

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Meningococcal Infections (th…20%
Open-enrollment share among volume-matched conditions near Meningococcal Infections

Meningococcal Infections lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Meningococcal Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Meningococcal Infections is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Meningococcal Infections research.

    Sanofi Pasteur, a Sanofi Company accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.

  3. Typical Meningococcal Infections enrolment sits around 810 participants.

    Median target enrolment is 810 among the 5 trials that report a genuine target (sentinel values excluded). 0 of those (0%) plan for fewer than 100 participants.

  4. Meningococcal Infections research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22Phase 32

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 2

Top Sponsors

Named interventions

Most-linked intervention names on Meningococcal Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Biological
1 trials
Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide Biological
1 trials
Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine Biological
1 trials
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Biological
1 trials
Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Biological
1 trials
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine Biological
1 trials
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate Biological
1 trials
Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide Biological
1 trials

US sites by state

Facility locations filed on Meningococcal Infections trials. A trial with sites in several states counts in each.

Kentucky 4 trials
Arizona 4 trials
Washington 2 trials
Utah 2 trials
Ohio 2 trials
New Mexico 2 trials
Nebraska 2 trials
Missouri 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Meningococcal Infections page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Meningococcal Infections condition card totals 5 registered trials; most-linked intervention Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate; top US site state Kentucky. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.